Dustin Kiker, MD
Gastroenterology · Cedar Park, TXNPI 1730362807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,231 of the $51,791 with a category attached, or 70.0%. AbbVie accounts for 88.4% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $28,607 and has fallen 93.2% since, to $1,955 in 2025. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $114.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$689
- Bristol Myers Squibb$562
- Johnson & Johnson$546
- Boston Scientific$432
- Madrigal Pharmaceuticals$415
- plus $3K from 35 others
Across 10 payments — averaging $28,790 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$282K
- E.r. Squibb & Sons, L.L.C.$6K
What the payments were for
- Speaking & faculty fees$36,23170%
- Travel & lodging$5,65611%
- Food & beverage$9,83319%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$18,035
- Axonics$135
- IBSRELA$121
- EXALT Model D$107
How this compares
$51,791 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $424,586 |
| ZenpepLipase/Protease/Amylase | 11 | $32,360 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 150 | $9,483 |
| Pantoprazole Sodium | 159 | $1,392 |
| Colestipol Hcl | 26 | $1,058 |
| Famotidine | 50 | $1,011 |
| Omeprazole | 47 | $609 |
| Esomeprazole Magnesium | 16 | $313 |
| Sucralfate | 13 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $546 | $424,58616 claims |
| Aimmune Therapeutics, Inc.Zenpep | $49 | $32,36011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Cedar Park
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.